Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093586 · ClinicalTrials.gov registry record · Phase 2
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01093586 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 14 participants.
The verdict
NCT01093586, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor umbilical cord blood stem cell transplant works in treating patients with hematologic malignancies.
Interventions
- DRUG busulfan
- PROCEDURE bone marrow aspiration
- OTHER cytogenetic analysis
- PROCEDURE double-unit umbilical cord blood transplantation
- OTHER fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093586
The ClinicalTrials.gov registry entry for NCT01093586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which busulfan is the first listed.
NCT01093586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093586 about?
NCT01093586 is a clinical study titled "Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies". RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from an unrelated donor, that do not exactly match the patient...
What is the current status of trial NCT01093586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01093586?
The interventions under investigation include: busulfan (DRUG), bone marrow aspiration (PROCEDURE), cytogenetic analysis (OTHER), double-unit umbilical cord blood transplantation (PROCEDURE), fluorescence in situ hybridization (OTHER).
Who is sponsoring clinical trial NCT01093586?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.